Neurofeedback has accumulated decades of research with effect sizes that remain modest and applications that remain uneven. The strongest evidence is in ADHD, where multiple meta-analyses show modest effects on attention with substantial heterogeneity across studies. Other applications — anxiety, depression, PTSD, performance optimization — have mixed evidence with smaller effect sizes. The clinical task is to engage neurofeedback honestly: legitimate adjunct in selected indications, not transformative intervention as sometimes marketed.
The ADHD evidence is the strongest application. Theta/beta neurofeedback protocols in ADHD have meta-analytic effect sizes around 0.3-0.5 for inattention and hyperactivity, comparable to non-stimulant medications. The Mayo Clinic and other rigorous programs have produced replicated benefit; the effect is real though modest. The patient with ADHD who cannot or prefers not to use stimulants, who has time and resources for the substantial treatment course (typically 30-40 sessions), and who has access to a quality program is a reasonable candidate.
Other applications have less consistent evidence. Anxiety neurofeedback shows benefit in some studies, no difference from sham in others. PTSD neurofeedback has emerging evidence with limited replication. Depression neurofeedback has mixed results. Performance optimization in healthy populations has small effect sizes when present. The heterogeneity across studies and the methodological variability of neurofeedback protocols make summary statements difficult; the evidence is suggestive in places but does not support routine prescription.
The clinical and practical considerations. Treatment course is substantial — 30-40 sessions typical, 60+ minutes each, twice weekly. Cost is substantial ($75-150 per session typically; $3000-6000+ for full course; not insurance-covered in most cases). Provider quality varies; trained providers with appropriate equipment differ substantially from less rigorous practices. The patient who is engaging neurofeedback should have realistic expectations about modest effects, time commitment, and cost.
The integration with broader treatment. Neurofeedback is adjunct, not substitute. The behavioral foundation — sleep, exercise, dietary patterns, stress management, evidence-based psychotherapy, medication when appropriate — produces larger effects than neurofeedback alone. The patient who is using neurofeedback alongside optimized foundational interventions may experience additive benefit; the patient who is using neurofeedback instead of evidence-based treatment is misallocating resources. The clinical conversation maintains the integrated frame. The discipline is to engage neurofeedback honestly — recognize the modest effect sizes, acknowledge the strongest application (ADHD), recommend in appropriate contexts with realistic expectations, and continue to direct attention to the foundational interventions that matter more.